deltatrials
Recruiting PHASE1 INTERVENTIONAL 1-arm NCT07108114

SLV-324 Treatment of Metastatic Solid Tumors

A Phase 1 Dose-Escalation Study of SLV-324 in Subjects With Metastatic Solid Tumors

Sponsor: Solve Therapeutics

Conditions Metastatic Solid Tumors
Interventions SLV-324 intravenous (IV infusion)
Updated 4 times since 2025 Last updated: Feb 20, 2026 Started: Aug 25, 2025 Primary completion: May 31, 2027 Completion: Aug 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Metastatic Solid Tumors, this trial is actively recruiting participants. The trial is conducted by Solve Therapeutics and has accumulated 4 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshotNot Yet Recruiting~Oct 2025 – ~Jan 2026 · 3 months · monthly snapshotRecruiting~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshotRecruiting~Feb 2026 – present · 5 months · monthly snapshotRecruiting

Change History

4 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE1

  2. Jan 2026 — Feb 2026 [monthly]

    Recruiting PHASE1

  3. Oct 2025 — Jan 2026 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  4. Sep 2025 — Oct 2025 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Aug 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Solve Therapeutics
Data source: Solve Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations